Clinical improvement in psoriasis with specific targeting of interleukin-23

Nature

Volumn 521, Issue 7551, 2015, Pages 222-226

  Kopp, Tamara ^a,b   Riedl, Elisabeth ^a   Bangert, Christine ^a   Bowman, Edward P ^c   Greisenegger, Elli ^a   Horowitz, Ann ^c   Kittler, Harald ^a   Blumenschein, Wendy M ^c   McClanahan, Terrill K ^c   Marbury, Thomas ^d   Zachariae, Claus ^e   Xu, Danlin ^c   Hou, Xiaoli Shirley ^c   Mehta, Anish ^c   Zandvliet, Anthe S ^c   Montgomery, Diana ^c   Van Aarle, Frank ^c   Khalilieh, Sauzanne ^c  

^a Universitatsklinik fur Dermatologie   (Austria)

^b Juvenis Medical Center   (Austria)

^c MERCK RESEARCH LABORATORIES   (United States)

^d ORLANDO CLINICAL RESEARCH CENTER   (United States)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 17; INTERLEUKIN 17F; INTERLEUKIN 22; INTERLEUKIN 23; INTERLEUKIN 23P19; PLACEBO; TILDRAKIZUMAB; TUMOR NECROSIS FACTOR; MONOCLONAL ANTIBODY; PROTEIN SUBUNIT;

DISEASE PREVALENCE; DISEASE SEVERITY; HISTOLOGY; IMMUNE RESPONSE; PSYCHOLOGY;

ADULT; AGED; ARTHRALGIA; ARTICLE; CONTROLLED STUDY; CONVULSION; COUGHING; CYTOKINE RELEASE; DISEASE SEVERITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; FOLLOW UP; GAMMA DELTA T LYMPHOCYTE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LOW DRUG DOSE; LYMPHOID CELL; MAJOR CLINICAL STUDY; MAST CELL; MULTICENTER STUDY; NATURAL KILLER CELL; NATURAL KILLER T CELL; NEUTROPHIL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; RANDOMIZED CONTROLLED TRIAL; REGULATORY T LYMPHOCYTE; RHINOPHARYNGITIS; TH17 CELL; TH22 CELL; UPPER RESPIRATORY TRACT INFECTION; ADOLESCENT; ANTAGONISTS AND INHIBITORS; CHEMISTRY; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; EPITHELIUM; GENE EXPRESSION REGULATION; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PROTEIN SUBUNIT; SKIN; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; DOUBLE-BLIND METHOD; EPITHELIUM; GENE EXPRESSION REGULATION; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-23; MIDDLE AGED; MOLECULAR TARGETED THERAPY; PROTEIN SUBUNITS; PSORIASIS; SKIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84929359284     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature14175     Document Type: Article

References (33)

1. Schön, M. P. & Boehncke, W. H. Psoriasis. N. Engl. J. Med. 352, 1899-1912 (2005).
2. Lowes, M. A., Bowcock, A. M. & Krueger, J. G. Pathogenesis andtherapy of psoriasis. Nature 445, 866-873 (2007).
3. Krueger, G. et al. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch. Dermatol. 137, 280-284 (2001).
4. Leonardi, C. L. et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 371, 1665-1674 (2008).
5. Papp, K. A. et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 371, 1675-1684 (2008).
6. Toichi, E. et al. An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12/IL-23 in psoriasis. J. Immunol. 177, 4917-4926 (2006).
7. Oppmann, B. et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 13, 715-725 (2000).
8. Lee, E. et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J. Exp. Med. 199, 125-130 (2004).
9. Chan, J. R. et al. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J. Exp. Med. 203, 2577-2587 (2006).
10. Lowes, M. A., Suárez-Fariñas, M. & Krueger, J. G. Immunology of psoriasis. Annu. Rev. Immunol. 32, 227-255 (2014).
11. Villanova, F. et al. Characterization of innate lymphoid cells in human skin and blood demonstrates increase of NKp44+ ILC3 in psoriasis. J. Invest. Dermatol. 134, 984-991 (2014).
12. Keijsers, R. R. et al. Balance of Treg vs. T-helper cells in the transition from symptomless to lesional psoriatic skin. Br. J. Dermatol. 168, 1294-1302 (2013).
13. Krueger, J. G. et al. IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis. J. Allergy Clin. Immunol. 130, 145-154 (2012).
14. Hueber, W. et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci. Transl. Med. 2, 52ra72 (2010).
15. Ngiow, S. F., Teng, M. W. & Smyth, M. J. A balance of interleukin-12 and -23 in cancer. Trends Immunol. 34, 548-555 (2013).
16. Bustamante, J., Picard, C., Boisson-Dupuis, S., Abel, L. & Casanova, J. L. Genetic lessons learned from X-linked Mendelian susceptibility to mycobacterial diseases. Ann. N. Y. Acad. Sci. 1246, 92-101 (2011).
17. Papp, K. A. et al. Long-term safety of ustekinumab in patients with moderate-tosevere psoriasis: final results from 5 years of follow-up. Br. J. Dermatol. 168, 844-854 (2013).
18. United States Food and Drug Administration. Guidance for Industry; Assay Development for Immunogenicity Testing of Therapeutic Proteins. Available at http://www.fda.gov/downloads/Drugs/Guidances/UCM192750.pdf (2009).
19. Torzicky, M. et al. Platelet endothelial cell adhesion molecule-1 (PECAM-1/CD31) and CD99 are critical in lymphatic transmigration of human dendritic cells. J. Invest. Dermatol. 132, 1149-1157 (2012).
20. Trozak, D. J. Histologic grading system for psoriasis vulgaris. Int. J. Dermatol. 33, 380-381 (1994).
21. Wolk, K. et al. The Th17 cytokine IL-22 induces IL-20 production in keratinocytes: a novel immunological cascade with potential relevance in psoriasis. Eur. J. Immunol. 39, 3570-3581 (2009).
22. Sa, S. M. et al. The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis. J. Immunol. 178, 2229-2240 (2007).
23. Guttman-Yassky, E. et al. Low expression of the IL-23/Th17 pathway in atopic dermatitis compared to psoriasis. J. Immunol. 181, 7420-7427 (2008).
24. Liang, S. C. et al. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J. Exp. Med. 203, 2271-2279 (2006).
25. Homey, B. et al. Up-regulation of macrophage inflammatory protein-3 α/CCL20 and CC chemokine receptor 6 in psoriasis. J. Immunol. 164, 6621-6632 (2000).
26. Lew, W., Lee, E. & Krueger, J. G. Psoriasis genomics: analysis of proinflammatory (type 1) gene expression in large plaque (Western) and small plaque (Asian) psoriasis vulgaris. Br. J. Dermatol. 150, 668-676 (2004).
27. Fredriksson, T. & Pettersson, U. Severe psoriasiseoral therapy witha new retinoid. Dermatologica 157, 238-244 (1978).
28. Langley, R. G. Effective and sustainable biologic treatment of psoriasis: what can we learn from new clinical data? J. Eur. Acad. Dermatol. Venereol. 26 (suppl. 2), 21-29 (2012).
29. Stary, G., Bangert, C., Stingl, G. & Kopp, T. Dendritic cells in atopic dermatitis: expression of FcepsilonRI on two distinct inflammation-associated subsets. Int. Arch. Allergy Immunol. 138, 278-290 (2005).
30. Ackerman, A. B., Boer, A., Bennin, B. & Gottlieb, G. J. Histologic Diagnosis of Inflammatory Skin Diseases: an Algorithmic Method Based on Pattern Analysis 3rd edn (Ardor Scribendi, 2005).
31. Bangert, C., Friedl, J., Stary, G., Stingl, G. & Kopp, T. Immunopathologic features of allergic contact dermatitis in humans: participation of plasmacytoid dendritic cells in the pathogenesis of the disease? J. Invest. Dermatol. 121, 1409-1418 (2003).
32. Bangert, C. et al. Clinical and cytological effects of pimecrolimus cream 1% after resolution of active atopic dermatitis lesions by topical corticosteroids: a randomized controlled trial. Dermatology 222, 36-48 (2011).
33. Skvara, H. et al. The PKC inhibitor AEB071 may be a therapeutic option for psoriasis. J. Clin. Invest. 118, 3151-3159 (2008).